5T4 is an attractive target for cancer therapeutics, especially with the emergence of increasing evidence showing that 5T4 is expressed on tumor‐initiating cells and associated with worse clinical outcome.35 Multiple therapeutic modalities targeting 5T4 have been in preclinical or clinical studies, including vaccines,36 CAR‐Ts,37 superantigens,38 and ADCs.21, 22, 23, 24 In this study, we developed a novel potent ADC (ZV0508) targeting 5T4 using a MMAF derivative (Duo‐5), via a proprietary interchain cysteine rebridging method named C‐LockTM conjugation. This evidence concerns the gene TPBG and neoplasm.